Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Normal Donors

Long-term donor health and its relationship with outcome of allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation volume 37, pages 451–453 (2006)Cite this article

Abstract

Data on long-term follow-up of donors for hematopoietic stem cell transplantation (HSCT) are limited. Donors of 612 adult allogeneic HSCT were studied, at a median of 81 (14–181) months post-HSC donation. Nine donors had severe health problems. Five donors died from aggressive malignancies or terminal illness, at a median of 41 (16–57) months post-donation. Notably, all their recipients had leukemic relapses. In contrast, donors of recipients in remission were all living. This observation might be due to an inherent depressed immunosurveillance in the donors, or selection of donors with suboptimal health for desperate patients with poor risks pre-HSCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Cleaver SA, Warren P, Kern M, Hurley CK, Raffoux C, Keller J et al. Donor work-up and transport of bone marrow – recommendations and requirements for a standardized practice throughout the world from the Donor Registries and Quality Assurance Working Groups of the World Marrow Donor Association (WMDA). Bone Marrow Transplant 1997; 20: 621–629.

    Article  CAS  Google Scholar 

  2. Niederwieser D, Gentilini C, Hegenbart U, Lange T, Moosmann P, Ponisch W et al. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? Bone Marrow Transplant 2004; 34: 657–665.

    Article  CAS  Google Scholar 

  3. Egeland T, Lie J, Persson U, Raymond J, Muller C . Donor and liability insurance of donor registries, donor centers, and collection centers – recommendations. Bone Marrow Transplant 2004; 33: 467–470.

    Article  CAS  Google Scholar 

  4. Rosenmayr A, Hartwell L, Egeland T . Informed consent – suggested procedures for informed consent for unrelated haematopoietic stem cell donors at various stages of recruitment, donor evaluation, and donor workup. Bone Marrow Transplant 2003; 31: 539–545.

    Article  CAS  Google Scholar 

  5. Au WY, Wong RW, Wong BC, Lie AK, Liang R, Leung AY et al. Reduced incidence of acute graft versus host disease (GVHD) of the gut in Chinese carriers of Helicobacter pylori during allogeneic bone marrow transplantation. Ann Hematol 2004; 83: 34–37.

    Article  CAS  Google Scholar 

  6. Au WY, Chan EC, Siu LL, Lau TC, Lie AK, Ma SK et al. Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol 2002; 119: 777–780.

    Article  CAS  Google Scholar 

  7. Strauss RG . Rationale for medical director acceptance or rejection of allogeneic plateletpheresis donors with underlying medical disorders. J Clin Apher 2002; 17: 111–117.

    Article  Google Scholar 

  8. Kiss TL, Chang H, Daly A, Messner HA, Jamal N, Spaner D et al. Bone marrow aspirates as part of routine donor assessment for allogeneic blood and marrow transplantation can reveal presence of occult hematological malignancies in otherwise asymptomatic individuals. Bone Marrow Transplant 2004; 33: 855–858.

    Article  CAS  Google Scholar 

  9. Buell JF, Beebe TM, Trofe J, Gross TG, Alloway RR, Hanaway MJ et al. Donor transmitted malignancies. Ann Transplant 2004; 9: 53–56.

    PubMed  Google Scholar 

  10. Favre G, Beksac M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32: 873–880.

    Article  CAS  Google Scholar 

  11. Bakken R, van Walraven AM, Egeland T . Donor commitment and patient needs. Bone Marrow Transplant 2004; 33: 225–230.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China

    W-Y Au, A K W Lie, J W Cheng, R Liang & Y-L Kwong

Authors
  1. W-Y Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A K W Lie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J W Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y-L Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y-L Kwong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Au, WY., Lie, A., Cheng, J. et al. Long-term donor health and its relationship with outcome of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37, 451–453 (2006). https://doi.org/10.1038/sj.bmt.1705274

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705274

Keywords

This article is cited by

Search

Advanced search

Quick links